RecruitingPhase 1NCT05587205
Safety and Tolerability of EO2002
Phase 1, Randomized, Masked, Sham-Controlled Study to Assess the Safety and Tolerability of EO2002 in Subjects Undergoing Cataract Surgery
Sponsor
Asociación para Evitar la Ceguera en México
Enrollment
32 participants
Start Date
Aug 30, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Age ≥ 18 years.
- Subject has uncomplicated history of cataract that has progressed to a level requiring standard cataract extraction with intraocular lens implant surgery.
- Decreased endothelial cell count
Exclusion Criteria12
- All ocular criteria apply to study eye unless otherwise noted.
- Other corneal disease
- Macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.
- Descemet membrane detachment.
- History of uveitis or other ocular inflammatory disease.
- History of incisional glaucoma surgery
- Prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty.
- History of ocular neoplasm.
- ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20/200).
- Female who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study.
- Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration.
- Any concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opinion of the investigator.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALEO2002
Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery
OTHERSham injection
Sham injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05587205
Related Trials
Artificial Intelligence for Highly Myopic Cataract
NCT066165061 location
Shanghai High Myopia Study
NCT030620851 location
Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice
NCT070150342 locations
Dexmedetomidine and Propofol for Sedation in Cataract Surgery.
NCT075561331 location
Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients
NCT071264703 locations